Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 14/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801210 | 0.76 | DYRK1A (0.36) | PTK2TSHRL3MBTL1DYRK1AALDH1A1 | |
| SCHEMBL24109419 | 0.76 | DYRK1A (0.36) | PTK2BRD4TSHRL3MBTL1DYRK1A | |
| SCHEMBL17354057 | 0.76 | DYRK1A (0.36) | PTK2BRD4TSHRL3MBTL1DYRK1A | |
| SCHEMBL29049545 | 0.76 | KDR (0.40) | ALDH1A1 | |
| SCHEMBL9802765 | 0.73 | PTK2 (0.47) | PTK2BRD4TSHRL3MBTL1DYRK1A | |
| SCHEMBL18463875 | 0.73 | PTK2 (0.37) | PTK2TSHRL3MBTL1DYRK1A | |
| SCHEMBL1663484 | 0.72 | PTK2 (0.46) | PTK2TSHRL3MBTL1DYRK1AALDH1A1 | |
| SCHEMBL24109425 | 0.72 | DHODH (0.40) | PTK2BRD4TSHRL3MBTL1DYRK1A | |
| SCHEMBL4903460 | 0.71 | BRD4 (0.50) | BRD4TSHRL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6304807 | 0.71 | TSHR (0.52) | PTK2TSHRL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2771321-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | PTK2 2380/4885BRD4 84/4885TSHR 2631/4885 |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | PTK2 8/4885BRD4 2455/4885TSHR 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.